Alnylam advances hypercholesterolemia drug with Tekmira's drug-delivery tech; Jazz Pharma taps drug-delivery vet to head R&D;

> The University of Michigan's Mohamed El-Sayed, Sophia Merajver and Yasmin Yuksel Durmaz has been awarded a $180,000 grant from Susan G. Komen for the Cure to advance drug-delivery vehicles to transport growth-inhibiting drugs to breast cancer tumors. Release

> InSite Vision has tapped Quintiles to run a Phase III clinical trial of AzaSite Plus and DexaSite for treating blepharitis. The products are formulated with a drug-delivery platform called DuraSite. Item

> Alnylam ($ALNY) has started giving patients its RNAi therapy ALN-PCS, which uses drug-delivery technology from Tekmira, in a Phase I trial. The drug is in development for treating severe hypercholesterolemia. Announcement

> Oramed Pharmaceuticals, which develops technology that enables oral delivery of meds that are now available by injection, said its tech licensee Entera succeeded in a Phase I study of an oral osteoporosis drug. Report

> Jazz Pharmaceuticals ($JAZZ) said it has tapped Jeffrey Tobias to be its head of R&D and chief medical officer, and the former NeurogesX executive comes to the job with drug-delivery experience. Release

> Celatorr Pharmaceuticals said that it has been granted a U.S. patent for intellectual property that supports its lead drug against leukemia, CPX-351, which combines cytarabine and daunorubicin with a liposome formulation. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.